Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 16/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888854 | 0.84 | TACR1 (0.46) | TACR1TACR3ACEMEN1KMT2A | |
| SCHEMBL8894222 | 0.83 | TACR1 (0.48) | TACR1TACR3 | |
| SCHEMBL8892928 | 0.81 | TACR1 (0.57) | TACR1TACR3 | |
| SCHEMBL9293660 | 0.80 | TACR1 (0.48) | TACR1TACR3 | |
| SCHEMBL8893578 | 0.79 | TACR1 (0.51) | TACR1TACR3 | |
| SCHEMBL8705433 | 0.79 | TACR1 (0.46) | TACR1TACR3MEN1KMT2AADRB3 | |
| SCHEMBL9293320 | 0.78 | TACR1 (0.45) | TACR1TACR3ACEADRB3 | |
| SCHEMBL8894105 | 0.78 | TACR1 (0.51) | TACR1TACR3 | |
| SCHEMBL9293315 | 0.77 | TACR1 (0.45) | TACR1TACR3ACEADRB3 | |
| SCHEMBL8715705 | 0.75 | TACR1 (0.46) | TACR1TACR3ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5593967-A | Cholecystokinin antagonists, their preparation and therapeutic use | WARNER-LAMBERT COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1992004045-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |